drugset
Drugs / AZD7648
last change Dec 2022 re-read 2 minutes ago

AZD7648

also known as 7-METHYL-2-({7-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YL}AMINO)-9-(OXAN-4-YL)-8,9-DIHYDRO-7H-PURIN-8-ONE · 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one

Small molecule

Developed for
cancer
Investigated by
AstraZeneca · Parexel

Trials 1 · a red edge is where a trial was stopped

today NCT03907969 · Ph 1/2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03907969 Oct 2019 → Dec 2022 cancer AstraZeneca Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as AZD7648 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03907969 ↗
Known as 7-METHYL-2-({7-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YL}AMINO)-9-(OXAN-4-YL)-8,9-DIHYDRO-7H-PURIN-8-ONE ChEMBL registry synonym — accepted as the source's own label CHEMBL4439259 ↗
Known as 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one “7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein...” PMID 31851518 ↗ Jan 2020
Modality Small molecule — CHEMBL4439259 ↗
Route Oral “administered orally” NCT03907969 ↗